These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 10823365)

  • 1. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Snyder EH; Bala MV; Richter A; Mauskopf JA
    Pharmacoeconomics; 2000 Apr; 17(4):351-60. PubMed ID: 10947490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Linkins KW; Lloyd JR; Hjelmstad GO; Strausbaugh HJ
    Pharmacoeconomics; 2000 Dec; 18(6):609-12. PubMed ID: 11227398
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
    Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
    Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
    O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
    J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications.
    Baladi JF; Bailey PA; Black S; Bouchard RW; Farcnik KD; Gauthier S; Kertesz A; Mohr E; Robillard A
    Clin Ther; 2000 Dec; 22(12):1549-61. PubMed ID: 11192146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
    Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
    Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.
    Gabelli C
    Curr Med Res Opin; 2003; 19(2):69-82. PubMed ID: 12740150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of rivastigmine: a reversible cholinesterase inhibitor.
    Williams BR; Nazarians A; Gill MA
    Clin Ther; 2003 Jun; 25(6):1634-53. PubMed ID: 12860489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.
    Willan AR; Goeree R; Pullenayegum EM; McBurney C; Blackhouse G
    Pharmacoeconomics; 2006; 24(1):93-106. PubMed ID: 16445306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.
    Desai A; Grossberg G
    Expert Opin Pharmacother; 2001 Apr; 2(4):653-66. PubMed ID: 11336614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.